6-K from Teva Pharma Shows Letter from CEO Vigodman, Chair Peterburg to Mylan Chair Coury

June 8, 2015 Robert J. Coury Executive Chairman Mylan N.V. Albany Gate, Darkes Lane Potters Bar, Herts EN6 1AG, United Kingdom Dear Robert, We are writing in response to your letter of June 1, 2015. We wholeheartedly agree with you that Mylan's stockholders deserve a fair and fully-informed opportunity to weigh the Teva proposal, which offers a substantial premium, immediate cash value and significant upside potential in a financially and commercially stronger company, as compared to the proposed Perrigo transaction. Contrary to your claim that we are doing little more than "meddling," our proposal is strong and serious, offers exceptional opportunity for Mylan's and Teva's stockholders and other stakeholders and deserves careful review and engagement by your board and your stockholders. The picture that you have been creating is a desperate attempt to prevent this from happening, as clearly demonstrated by your actions and commentary on a number of subjects noted below: • Refusal to Allow Stockholders to Consider Teva Proposal. You have continued to take steps towards a vote on the Perrigo transaction while pretending that a more attractive and valuable option does not exist. You have been quoted as saying in analyst meetings that you intend to put your stockholders in a "tough place" by forcing them to consider the Perrigo transaction without allowing them to consider the Teva proposal. • Unwillingness to Provide Stockholders with Complete Information About the Proposals. You are asking your stockholders to vote on the Perrigo transaction with a lack of transparency, depriving them of a fair and honest financial analysis of the Teva proposal as compared to the proposed Perrigo transaction. At the same time, you continue to make confounding statements about wanting to be acquired by Novartis or Pfizer. • Governance. You have repeatedly said that the Mylan board is able and willing to use Mylan's unprecedented governance structure to prevent a serious buyer from succeeding in a transaction. These statements are both inconsistent with Dutch corporate governance standards and misleading to Mylan's stockholders. Your comments are merely aimed at frustrating Teva and denying your stockholders the ability to consider the Teva proposal. • Attempting to Paint Teva in a Negative Light. You have continually made grossly incorrect statements about Teva to mislead your stockholders and other stakeholders about us. • Teva is stronger than ever. The proven results from recent actions that Teva has taken demonstrate that Teva is stronger than ever, both in its generic and specialty businesses. We have significantly strengthened the fundamentals of our company, solidified our key franchises, put in place robust engines for growth and provided a clear roadmap to further reinforce our industry-leading position. Your repeated statements regarding Teva's prospects are wholly inaccurate. We are vigorously and successfully protecting our core franchises. Our specialty pipeline is in the best shape it has ever been and we continue to bolster it relentlessly. So are our capabilities in generics. Like product portfolios of many other leading pharmaceutical companies, our portfolio is also changing. • Value creation and integration of acquired companies. In the last two decades, Teva has transformed the generics space, setting the industry standards for others to follow. In doing that, it generated returns for our stockholders in excess of 1600%, one of the highest rates in the pharmaceutical industry. This performance has been achieved through both organic growth and large global and diverse acquisitions that required successful integration of cultures, activities, businesses and assets in numerous territories. The unique experience Teva has gained from the more successful (and sometimes also less successful) acquisitions is fully applied in everything we are doing, and we will continue to do so. • Diversity and globalization. Teva is a truly global, highly diverse company with a unique combination of cultures, geographies and businesses. It starts with its diverse top leadership team and goes all the way throughout the ranks. Israel has a significant role in Teva's legacy and culture, and it has been contributing substantially to its success. At the same time, as in any of the other countries in which it operates, Teva invests in Israel in those activities that create value and enhance competitiveness to the company on a global level. • Compliance with the law. Teva's acquisition of Mylan shares is in compliance with applicable law. We have conferred with the U.S. antitrust authorities and have been given no reason to believe that our purchases violate the Hart-Scott-Rodino Act or any other U.S. antitrust laws. In the meantime, we note that you have been saying you are a Dutch company when you believe it helps you create unprecedented governance structures, a U.K. company when it helps you lower your U.S. taxes and a U.S. company when you believe it helps you prevent Teva from purchasing Mylan shares. • Teva's corporate governance. We are responsive to our stockholders and practice good corporate governance principles. Within the past year, Teva has profoundly changed its board of directors, and led by its new Chairman of the Board continues to substantially enhance its governance profile. • Other stakeholders. Teva is highly committed to providing affordable treatments to patients and communities worldwide and is constantly exploring opportunities and implementing strategies to better serve its patients, customers and employees. In particular, Teva has no plans to close down Mylan's West Virginia facility after the completion of the transaction. • Growth versus cost reductions. Teva's proposal to acquire Mylan will drive significant value and growth generation in the combined company's generic and specialty businesses, in addition to the achievement of meaningful cost synergies and efficiencies. The resources we will be able to generate from the combination will be invested in compelling growth opportunities, in generics and specialty, creating ample benefits and opportunities to Mylan's and Teva's stockholders, employees and other stakeholders. There is nothing unclear or equivocal about Teva's intentions. We have a clear roadmap to deliver on our proposal, and we remain committed to taking all of the steps necessary to deliver the exceptional benefits of this combination to the stockholders of Mylan and Teva, as well as the other stakeholders of both companies. While our desire remains to reach agreement on a transaction, we will continue to take the steps necessary to accomplish our proposal, which will create substantial long-term value and an opportunity to better serve our respective patients, customers, employees and communities around the world. Sincerely, /s/ Erez Vigodman /s/ Prof. Yitzhak Peterburg Erez Vigodman Prof. Yitzhak Peterburg President & Chief Executive Officer Chairman of the Board of Directors